Provider status update wegovy pill UK wegovy pill pre-orders from providers independent pharmacy wegovy pre-order news weight loss provider reviews
Wegovy pill provider status update: Curate Health moves to coming soon
Today’s provider check found one clear movement in the UK Wegovy pill market: Curate Health now shows public wording for a Wegovy pill / semaglutide daily tablet route and describes it as coming soon.
That is a real change from the previous check, where no public Wegovy pill mention was visible. It is not the same as commercial availability, a pre-order route or a confirmed supply route. The current public signal is earlier than that: the provider has started naming the tablet route, but has not shown a price, waitlist or ordering pathway in the material checked.
What changed
Curate Health now presents a Wegovy pill / semaglutide daily tablet area with “Weight loss pill coming soon” wording. That moves the provider from Not mentioned to Coming soon in TabletCompare’s Wegovy pill provider status tracker.
The important limit is that no waitlist, pre-order, price or available route was confirmed in this check. For visitors, this means Curate Health is now worth watching, but it should not be treated as a provider currently supplying the Wegovy pill.
| Provider | Previous status | Current status | What the change means |
|---|---|---|---|
| Curate Health | Not mentioned | Coming soon | Public Wegovy pill / semaglutide tablet wording is now visible, but no access route, price or stock signal was confirmed. |
What did not change
No provider moved into a confirmed Available state during today’s check. That matters because an availability move would trigger a higher-priority operational response, including a fresh update, profile refresh and alert review.
Other closely watched providers remain in their existing public-status groups, including pre-order, waitlist, coming soon, out of stock or not mentioned. Some provider pages still use stale or incomplete wording around MHRA approval, so TabletCompare continues to separate approval, commercial availability and NHS access rather than treating a single page label as the whole picture.
Why this kind of change matters
The Wegovy pill was MHRA-approved on 11 June 2026, but approval did not switch every provider page into a live supply route overnight. The market is moving in smaller steps: first public education pages, then coming-soon language, then waitlists, pre-orders, out-of-stock product pages and, eventually, confirmed availability.
Curate Health moving into coming-soon wording is one of those early public signals. It shows another provider preparing the category, but it does not prove stock, suitability, price or prescribing access.
TabletCompare view
This is a useful monitoring signal, not a launch signal. The next meaningful changes to watch are visible pricing, a clear waitlist or pre-order route, updated clinical assessment wording and any provider page that moves from “coming soon” into an explicit supply status.
What to check next
- Whether Curate Health adds a waitlist, price or consultation route.
- Whether current pre-order providers move into available or out-of-stock wording.
- Whether stale provider pages are updated to reflect the 11 June 2026 MHRA approval.
- Whether NHS access guidance changes separately from private-provider wording.
Information only. Wegovy tablets are prescription-only medicines. Provider pages can change quickly, and commercial availability is separate from MHRA approval and NHS access. Clinical assessment remains required before any prescription decision.